Equities research analysts forecast that Crispr Therapeutics AG (NASDAQ:CRSP) will post earnings of $0.04 per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Crispr Therapeutics’ earnings, with the highest EPS estimate coming in at $0.07 and the lowest estimate coming in at $0.01. Crispr Therapeutics posted earnings per share of ($0.92) in the same quarter last year, which would suggest a positive year over year growth rate of 104.3%. The company is scheduled to report its next quarterly earnings results on Monday, February 24th.
According to Zacks, analysts expect that Crispr Therapeutics will report full-year earnings of $0.65 per share for the current financial year, with EPS estimates ranging from $0.59 to $0.71. For the next financial year, analysts forecast that the company will post earnings of ($4.68) per share, with EPS estimates ranging from ($5.38) to ($3.67). Zacks’ EPS averages are an average based on a survey of research analysts that that provide coverage for Crispr Therapeutics.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%.
Several equities analysts recently issued reports on the company. Roth Capital upped their price objective on Crispr Therapeutics from $65.00 to $100.00 in a research report on Tuesday, November 19th. BidaskClub raised Crispr Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 30th. TheStreet upgraded Crispr Therapeutics from a “d” rating to a “c” rating in a research note on Monday, October 28th. Chardan Capital reaffirmed a “buy” rating and set a $72.50 price target on shares of Crispr Therapeutics in a report on Monday, November 18th. Finally, Oppenheimer increased their price objective on Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a research report on Monday, November 25th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $69.54.
In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $62.00, for a total value of $465,000.00. Following the transaction, the director now owns 7,500 shares of the company’s stock, valued at $465,000. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now directly owns 33,618 shares in the company, valued at $2,353,260. The disclosure for this sale can be found here. In the last ninety days, insiders sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in CRSP. BSW Wealth Partners bought a new position in shares of Crispr Therapeutics in the 2nd quarter worth approximately $39,000. Balyasny Asset Management LLC bought a new position in Crispr Therapeutics in the second quarter worth approximately $5,165,000. BNP Paribas Arbitrage SA bought a new position in Crispr Therapeutics in the second quarter worth approximately $41,000. Bank of New York Mellon Corp boosted its stake in shares of Crispr Therapeutics by 116.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 33,091 shares of the company’s stock worth $1,559,000 after acquiring an additional 17,810 shares during the last quarter. Finally, ARK Investment Management LLC boosted its stake in shares of Crispr Therapeutics by 34.7% during the 2nd quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock worth $128,317,000 after acquiring an additional 701,332 shares during the last quarter. 49.81% of the stock is owned by hedge funds and other institutional investors.
NASDAQ CRSP traded up $1.66 during mid-day trading on Monday, reaching $72.37. The stock had a trading volume of 892,934 shares, compared to its average volume of 703,877. Crispr Therapeutics has a 1 year low of $22.22 and a 1 year high of $74.00. The stock has a market cap of $4.00 billion, a PE ratio of -21.04 and a beta of 3.30. The company has a fifty day moving average price of $54.81 and a 200 day moving average price of $47.38. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: Momentum Indicators
Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
